The post-anti-VEGF era: a tens-billion-dollar “secret war”
Amino Observation
2026.11.20 12:37
· From Beijing
Full text 4871 words
Text | Amino Observation
An acquisition worth up to US$3.325 billion has added fuel to the iterative wave of new global ophthalmic drugs.
On November 16, Johnson & Johnson announced the acquisition of Ollin, an ophthalmic biotech company. Biosciences, with a down payment of US$2.2 billion and a consideration of up to US$1.125 billion in regulatory and commercial milestones, acquired two ophthalmic dual-antibody pipelines: one is the VEGF/Ang2 dual-antibody OLN324, which has been advanced to Phase III clinical trials and targets wet age-related macular degeneration (wAMD) and diabetic macular edema (DME); the other is the IGF-1R/TSHR dual-antibody OLN102 for thyroid eye disease (TED). The former comes from Cinda Biotech, and the latter comes from Chengfan Pharmaceuticals.
Looking back at the evolution trend of ophthalmology in the past 20 years, Eylea counterattacked and became the king of ophthalmic drugs by virtue of its better efficacy and compliance; Vabysmo aimed at the opportunity of the next generation of anti-VEGF ophthalmic drugs, and through longer dosing intervals, it became an instant hit after it was launched. OLN324 hopes to go one step further. Its dual-target design can control fundus angiogenesis more deeply, and has shown clinical advantages in head-to-head early studies with Vabysmo.
In other words, Johnson & Johnson is betting on the next big hit in ophthalmology. It is not difficult to understand. Driven by the dual drive of the aging population and the rising prevalence of diabetes, the ophthalmic drug market has already exceeded tens of billions of dollars. However, the treatment bottleneck of traditional anti-VEGF drugs has become increasingly prominent - the compliance problem of repeated intraocular injections, insufficient response in some patients, and long-term efficacy decay, which together constitute a clear unmet clinical need.
A clear enough market pain point is enough to create huge commercial returns, attracting large and small pharmaceutical companies at home and abroad to compete for the first place. Ollin’s pipeline is just the tip of the iceberg among many ophthalmic innovation pipelines. The research and development of global fundus drugs has already shifted from the “involution” of a single target to the multi-dimensional race of dual/multiple antibodies, long-acting sustained release and even gene therapy.
Ten billion dollar market and ceiling
In the ophthalmic drug landscape, fundus diseases are undoubtedly the most valuable field and are far from saturated.
According to data disclosed at EyePoint's 2025 Investor Day, the global market size of brand-name drugs for the three major indications of wet age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) has exceeded US$12 billion. Among them, the two major indications of nAMD and DME account for more than 80% and are the absolute main market forces.
The growth logic on the demand side is still solid. The aging of the population continues to push up the number of patients with macular degeneration. The expansion of the global diabetic patient base has steadily increased the demand for diagnosis and treatment of DME and diabetic retinopathy. Adding to the long-term eye disease burden of myopic people, the fundus disease market continues to expand.
However, the traditional anti-VEGF drugs that support this tens of billions of dollars market are hitting the ceiling of clinical limitations.
Taking nAMD and DME as examples, anti-VEGF drugs improve patient prognosis by inhibiting abnormal angiogenesis and vascular leakage. However, this type of disease usually requires long-term management, and patients often need to receive repeated intravitreal injections, resulting in poor compliance.
Especially for DME, a considerable number of patients still have insufficient clinical response to anti-VEGF treatment, and some patients cannot achieve sustained retinal fluid control during long-term treatment.
Extending the dosing interval, deep cleaning of fluid accumulation, and overcoming drug-resistant populations are three unmet clinical needs that form the core logic for the new generation of ophthalmic drugs to break through.
Vabysmo is the first "next generation" player to come out. As the world's first approved VEGF/Ang2 dual antibody, it targets VEGF-A and Ang2 at the same time. It not only inhibits abnormal angiogenesis, but also improves blood vessel stability. It is also effective for patients with insufficient response to previous anti-VEGF treatments.
The growth momentum of Vabysmo after its listing has verified the commercial value of this direction: in 2025, its global sales reached 4.102 billion Swiss francs, a year-on-year increase of 12%; in the third quarter of 2026, its sales reached 3.2 billion Swiss francs, a year-on-year increase of 10%, and it is still seizing market share from Eylea.
But Vabysmo is not the end. Currently, its initial treatment phase still requires injection every 4 weeks, and there is still room for further extension of the dosing interval in the maintenance phase. At the same time, reports of rare eye safety events such as retinal vasculitis have also appeared after marketing, and long-term safety still requires continuous monitoring.
In other words, between the huge market demand and existing treatments that still have shortcomings, the window for latecomers is still open.
A massive investment of US$3.3 billion, what does Johnson & Johnson see?
Faced with the huge potential of the ophthalmic drug market and clear clinical needs, multinational pharmaceutical companies have begun to increase their bets on the new generation of ophthalmic pipelines.
Johnson & Johnson’s US$3.3 billion acquisition of Ollin is essentially to strengthen its ophthalmic pipeline and use real money to directly win the core rights to compete in the next generation of ophthalmic drugs.
The structure of this deal is also worth pondering. In addition to the total consideration of US$2.2 billion in down payment and US$1.125 billion in milestones, Johnson & Johnson also simultaneously reached an independent research and development financing agreement with Blackstone. Blackstone will invest US$750 million to support the Phase III clinical development of OLN324 in exchange for corresponding milestone payments and single-digit sales shares.
The support of top investment institutions shows that they recognize the asset quality of OLN324. Whether it is structural design or early clinical performance, this dual antibody has the potential to impact BIC.
According to the information disclosed by Ollin, OLN32 is also a VEGF/Ang2 dual antibody, but uses a smaller antibody structure (minibody) and has higher Ang2 inhibitory potency. It can achieve more sufficient dual-target intervention at a higher molar dose, which can theoretically bring better retinal fluid control effects and longer duration of action.
The head-to-head clinical study of OLN324 and Vabysmo provides more direct evidence of efficacy.
In January 2026, Ollin announced phase Ib clinical data comparing OLN324 with Vabysmo in the treatment of patients with wAMD or DME: in patients with DME, the OLN324 4mg group showed faster and more significant improvement in retinal anatomy. At week 12, nearly 90% of patients achieved DME-free status, compared with 57% in the Vabysmo group.
In March, Ollin further announced 20 weeks of complete data. Among DME patients, the OLN324 treatment group still maintained a good retinal drying effect 12 weeks after the last mandatory administration. Among them, 93% of patients in the OLN324 4mg group did not require re-treatment, and 89% in the Vabysmo group.
In terms of visual acuity improvement, the OLN324 4mg group also maintained its advantage. In patients with wAMD, OLN324 4 mg was approximately 2.2 letters higher than Vabysmo in best-corrected visual acuity improvement at week 20. In addition, OLN324 also showed faster and longer-lasting results in improving pigment epithelial detachment (PED) thickness.
Whether it is anatomical improvement or visual improvement, OLN324 is superior to Vabysmo. Of course, this is only a Phase Ib study with limited sample size and follow-up time. OLN324 still needs larger-scale studies to verify its effectiveness. But the advantages shown in direct head-to-head comparisons are enough to support Johnson & Johnson's determination to make a bet.
Another preclinical pipeline IGF-1R/TSHR dual antibody OLN102 has supplemented Johnson & Johnson’s layout in the TED field.
TED is an orbital inflammatory disease closely related to autoimmune thyroid disease. Patients may experience proptosis, diplopia, eyelid retraction, and in severe cases, optic nerve compression and visual impairment.
IGF-1R is already a clinically proven therapeutic target. Tetuzumab (Tepezza) works by inhibiting IGF-1R and is the first approved non-surgical treatment for TED. OLN102 further adds TSHR inhibition on the basis of IGF-1R. TSHR plays an important role in the treatment of Graves' disease. It works synergistically with IGF-1R and has a theoretically stronger effect.
Based on this target combination, Innovent's same-target dual antibody IBI3031 has also advanced to Phase I clinical stage for indication research on TED.
The tide is surging, three main lines of innovation for the next generation of ophthalmic drugs
The Johnson & Johnson acquisition is just the tip of the iceberg. Looking around the world, the wave of research and development of innovative ophthalmic drugs has already surged. Multi-dimensional innovations in target mechanisms, delivery technologies, and treatment paradigms have gone hand in hand. The competition dimension has already jumped out of the traditional anti-VEGF framework.
·Target upgrade: from dual antibodies to multi-targets, comprehensive coverage of vascular pathology
From the perspective of targets, VEGF/Ang2 dual antibodies are currently the most mature and competitive direction. In addition to Vabysmo and OLN324 acquired by Johnson & Johnson, Boehringer Ingelheim's BI-836880 is a VEGF/Ang2 bispecific nanobody that uses a different molecular form from traditional bisAbs and has entered Phase I/II clinical development.
Xinqiao Biological's VIS-101 is also worthy of attention. This is a new quadrivalent bispecific antibody targeting VEGF-A and ANG-2. The quadrivalent molecular structure extends the half-life. Phase I data shows that half of the patients take medication more than 6 months. Recently, the product has just been announced to have been administered to the first patient in Phase IIb.
In addition to dual targets, a wider range of multi-target fusion proteins are also being promoted simultaneously. Kinsey Pharmaceutical's GenSci148 also covers four targets: VEGF-A, VEGF-C, VEGF-D and Ang2, and intervenes in abnormal angiogenesis, vascular permeability and stability from multiple pathways. This product has been clinically approved in China in August 2026.
Combinations are not limited to VEGF/Ang2 dual antibodies. Combinations of VEGF with FGF, complement, Tie2, IL-6 and other targets are also emerging.
Rongchang Biotech's RC28-E is a VEGF/FGF dual-target fusion protein that explores more comprehensive control of abnormal angiogenesis by simultaneously inhibiting VEGF and FGF-related signals.
Innovent's IBI302 adopts a design that combines VEGF and the complement pathway. It captures VEGF family ligands through VEGFR1 and VEGFR2-related domains and introduces complement inhibition-related functions, hoping to take into account pathological links such as angiogenesis and inflammatory injury.
Kodiak Sciences' Tabirafusp-ted (KSI-501) combines IL-6 with VEGF. This product inhibits abnormal angiogenesis through VEGF-trap and blocks IL-6-related inflammatory signals, improving the disease from the two dimensions of vascular abnormalities and inflammatory response. The product achieved the primary endpoint in the Phase III DAYBREAK study announced in September 2026, and the visual improvement was non-inferior to Eylea. Phase III clinical studies for DME are currently underway.
MK-8748, developed by Merck, simultaneously inhibits VEGF and activates Tie2, which is a receptor tyrosine kinase expressed on the surface of endothelial cells and is an important factor in maintaining the stability of vascular endothelium. This design further enhances blood vessel stability and reduces abnormal leakage, and has now entered Phase II/III clinical research.
·Gene therapy: a paradigm revolution that pursues “one dose, long-term benefits”
For patients with nAMD and DME, long-term and repeated intravitreal injections are an unavoidable problem. The logic of gene therapy is to allow retinal cells to continue to express therapeutic proteins through a single intraocular administration, thus solving the root cause of the pain points of repeated injections.
Several products have entered clinical stages around the world. Ixo-vec, acquired by Eli Lilly, is an AAV gene therapy product for nAMD. It enables retinal cells to continuously express anti-VEGF proteins through intraocular delivery, greatly reducing patients' dependence on conventional injections. In addition, through cooperation with MeiraGTx, Eli Lilly also obtained the gene therapy AAV-AIPL1 for the treatment of Leber congenital amaurosis type 4 (LCA4), with the goal of "restoring the vision of children who are destined to be blind at birth."
Domestic companies are also quickly following suit. Jian Bio's EXG102-031 adopts a broader anti-angiogenic design and delivers sustainable expression of therapeutic proteins covering multiple related pathways such as VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF and Ang2 through AAV, achieving More comprehensive vascular regulation than single VEGF inhibition; Dingxin Gene's RRG001 also uses AAV gene therapy strategy. Phase I/IIa study data shows that the annual anti-VEGF supplementary injection rate in the high-dose group dropped by 95.83%, showing the potential to reduce the burden of repeated treatments.
Of course, the druggability of AAV gene therapy still faces more unknown challenges. Immunogenicity, long-term expression stability, safety and even commercialization are all thresholds that need to be overcome. But once successfully verified, it will become a disruptive treatment solution in the field of fundus diseases.
·Exploration of new mechanisms: escape from VEGF and return to vascular homeostasis
Retinal fundus diseases are not just a problem of excessive vascularization. Impaired vascular barrier function, abnormal endothelial cell connections, and local inflammation are also involved in the development of the disease. Therefore, jumping out of the inherent idea of VEGF inhibition and activating pathways related to vascular homeostasis has become another innovative path.
Merck's MK-3000 is a representative in this direction. By simulating the role of the natural ligand Norrin, it activates the FZD4-related Wnt signaling pathway and promotes the normal development and stability of retinal blood vessels. Its key phase II/III study for DME has read out positive results.
In addition, long-acting delivery technology has also had high hopes, trying to extend the dosing interval through sustained-release preparations. But research and development in this direction has not been smooth sailing. Recently, EyePoint's DURAVYU (vorolanib intraocular sustained-release preparation) failed to meet the expected endpoint in Phase III clinical trials. The company's stock price plummeted by more than 80% in a single day, which also cast a shadow on the research and development prospects of long-acting ophthalmic delivery.
This reminds us once again that drug research and development for fundus diseases is entering a stage of all-round innovation. From the superposition and expansion of targets, to breakthroughs in delivery technology, to the innovation of treatment paradigms, players with different technical routes are competing on the same field. However, whether innovative mechanisms can be transformed into clinical advantages ultimately depends on effectiveness and safety data.
Of course, there is no doubt that the tens of billions of dollars in market space is enough to accommodate multiple blockbuster products, and a wave of ophthalmic innovation has already begun. So, after the big waves wash away the sand, who can become the next generation's king?
Respect for the original work, if you are qualified, you should be appreciated.
According to the real-name requirement of the Cybersecurity Law, please bind your mobile phone number before posting a comment.
Express
12:26
Xi Jinping meets with Malaysian Prime Minister Anwar
12:25
Xi Jinping meets with Australian Prime Minister Albanese
12:19
Xi Jinping meets with Indonesian President Prabowo
12:10
Youlu releases a property management multi-scenario robot product portfolio and will build 108 robots with ecological companies
12:04
Hong Kong stock midday review: Hang Seng Index fell 1.71%, Hang Seng Technology Index fell 3.14%
12:00
Digital platforms and new energy trucks enter the transportation scene, and road freight is ushering in new changes
Tencent Hunyuan officially opens source Hy4
11:48
Breaking the record, China achieves wireless communication verification with the highest code rate in the 6G frequency band
Malaysian Prime Minister Anwar arrived at the meeting
11:47
Xi Jinping meets with Thai Prime Minister Anutin
Qiyuan Robot signed a strategic cooperation with the Postal and Telecommunications Equipment Consumer Electronics Division
11:46
A-share lunch review: Shenzhen Component Index and ChiNext Index both fell by more than 2%, and the precious metals and liquor sectors performed sluggishly.
11:35
The relevant person in charge of Byte refutes rumors that Xie Xin and Zhang Nan have resigned: the information is inaccurate
11:32
The main domestic futures contracts rose or fell, with palladium and Shanghai silver falling nearly 9%.
11:28
Meta plans to launch Muse Charm, priced at $300
11:27
Spot gold fell below $3,520 per ounce, down nearly 3% on the day
11:23
Over 60% of China's sustainable development indicators are close to or achieving the 2030 goal
11:14
The concept of AI comic drama rebounded during the session, and Guomai Culture rose by more than 10%
11:13
Procter & Gamble plans to cut manufacturing and logistics employees by up to 30% by 2030
11:04
National Energy Group established a hydrogen energy technology company in Ordos with a registered capital of approximately 350 million
Scan to download App

